Steel Dynamics (NASDAQ:STLD) has provided its earnings guidance for the fourth quarter of fiscal year 2025, forecasting a range of $1.65 to $1.69 per diluted share.
This represents a notable decline from the $2.74 per share earnings reported in the third quarter of 2025, but an increase over the $1.36 per share reported in Q4 2024.
Coursera (NYSE:COUR) and Udemy (NASDAQ:UDMY) announced today that they have entered into a definitive merger agreement to combine in an all-stock transaction valued at approximately $2.5 billion.
Wiley (NYSE:WLY), a global leader in scientific content and research intelligence, has announced a quarterly cash dividend of $0.355 per share, effective January 15, 2026.
Nucor (NYSE:NUE) has provided its earnings guidance for the fourth quarter of fiscal year 2025, forecasting earnings per share (EPS) in the range of $1.65 to $1.75.
Jabil (NYSE:JBL) has reported preliminary, unaudited financial results for the first quarter of fiscal year 2026, posting strong performance with net revenue of $8.3 billion.
The company's U.S. GAAP operating income stood at $283 million, and U.S. GAAP diluted earnings per share (EPS) was $1.35.
Texas Pacific Land Corporation (NYSE:TPL) has announced a strategic partnership with Bolt Data & Energy (Bolt) to develop large-scale data center campuses and the necessary infrastructure across TPL land.
Warner Bros. Discovery (NASDAQ:WBD) has announced that its Board of Directors has unanimously rejected the tender offer launched by Paramount Skydance (NASDAQ:PSKY) on December 8, 2025.
ABM (NYSE:ABM) has announced its agreement to acquire WGNSTAR in a cash transaction valued at approximately $275 million.
Sealed Air (NYSE:SEE) announced the expiration of the 30-day go-shop period under its definitive merger agreement with funds affiliated with Clayton, Dubilier & Rice (CD&R) on December 16, 2025.
Merck (NYSE:MRK) announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy.
Pfizer (NYSE:PFE) and Astellas have announced positive topline results from the interim analysis of the Phase 3 EV-304 (KEYNOTE-B15) trial, evaluating the combination of PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).
Sinclair (NASDAQ:SBGI) issued a statement today in response to The E.W. Scripps Company (NASDAQ:SSP) rejecting its proposal for a potential merger.
